Now It Gets Real- Clinical Data in Advanced Cancer Patients Treated With an Individualized Neoantigen Vaccine

Time: 9:30 am
day: Day Two

Details:

  • Neoantigen-directed immunotherapy has been developed using high quality machine learning-enabled prediction of neoantigens plus viral vector-based delivery of select individualized neoantigens to patients with advanced solid tumors
  • A phase 1/2 trial has been conducted in the US/Australia to assess safety, immunogenicity and efficacy of this approach
  • Clinical data with up to a year of follow-up, with a focus on colorectal cancer, will be presented

Speakers:

Andrew Allen